Ebola in DR Congo: Cases Near 300 as Vaccine Gap Looms

In the hillside town of Bunia in northeastern Democratic Republic of Congo, a doctor watched five patients walk out of a treatment ward at the end of May, the first people to survive a confirmed case since the country's latest Ebola outbreak began. The discharges were a rare bright moment in a crisis that has moved with unusual speed. As of June 1, 2026, confirmed cases across the DRC are approaching 300, the toll is climbing, and the strain behind it all is one for which no approved vaccine or treatment exists.

The outbreak, declared on May 15, is caused by the Bundibugyo virus, a less common member of the Ebola family. Within roughly two weeks, the World Health Organization declared a public health emergency of international concern, and the agency's director-general flew to the epicenter himself. Suspected infections that surfaced in Brazil and Italy briefly raised fears of international spread before laboratory tests ruled them out.

A Fast-Moving Outbreak in Ituri Province

The epidemic is centered in Ituri Province, where three health zones, Mongbwalu, Rwampara, and Bunia, have accounted for the overwhelming majority of cases. The provincial capital, Bunia, is the epicenter. The virus has also reached the neighboring North Kivu and South Kivu provinces, and a small cluster of imported cases crossed into Uganda early in the outbreak.

The numbers have escalated quickly. In mid-May, the WHO logged only a handful of confirmed cases. By May 30, the confirmed count had climbed to 225 alongside more than 1,000 suspected cases. By early June, confirmed cases were nearing 300, with dozens of deaths recorded among them and hundreds more among the broad pool of suspected infections still awaiting laboratory confirmation. Medecins Sans Frontieres has described it as one of the fastest-spreading Ebola outbreaks ever recorded.

Several health workers have died, including four in the DRC within a single four-day stretch early in the response, a loss that strains an already thin medical workforce in a region long destabilized by armed conflict.

Why the Bundibugyo Strain Has No Vaccine

Most public attention to Ebola over the past decade has focused on the Zaire strain, the target of the licensed Ervebo vaccine and of approved antibody treatments that have transformed survival odds in recent outbreaks. The Bundibugyo virus is a different species, and those tools do not protect against it.

"Unlike Ebola virus disease, there is no licensed vaccine or specific therapeutics against" the Bundibugyo strain, the WHO noted in its outbreak assessment. The agency has cautioned that the strain's case fatality rate could reach 30 to 50 percent, based on past outbreaks, though the rate among confirmed cases in this event has so far run lower. Research efforts to advance candidate vaccines and treatments have been activated, but nothing is approved and ready for deployment.

That gap places enormous weight on supportive care, the management of fever, dehydration, and other symptoms that can keep a patient alive while the body fights the infection. The five recoveries in Bunia, four discharged on May 31 and one on May 29, were achieved through exactly that kind of symptomatic treatment.

The WHO Chief on the Ground in Bunia

WHO Director-General Tedros Adhanom Ghebreyesus arrived in Bunia on May 30 and attended the opening of the new Evangelical Medical Center treatment facility. His message leaned on the early recoveries as proof that the outbreak is survivable and stoppable.

"Of course, we're still working on vaccines and treatments, but that doesn't mean that people cannot recover from Ebola," Tedros said. "We can stop this Ebola and anyone who has it can also recover." On the role of local communities in the response, he added: "The communities understand the problems better, and they know the solution."

Congolese officials echoed the cautious optimism. "There is hope," said Pierre Akilimali of Congo's National Institute of Public Health, while a treatment center physician, Davin Ambitapio, stressed that the virus is manageable with prompt, dedicated care.

Containment Under Difficult Conditions

The DRC health ministry has expanded testing, contact tracing, and monitoring, with samples transported to the national biomedical research institute in Kinshasa for confirmation. The WHO has deployed rapid response teams, distributed infection-control and sample-collection kits, set up isolation facilities, and supported cross-border screening.

Containment has been complicated by the realities of Ituri. Armed groups, including the Allied Democratic Forces and M23 rebels, have attacked health teams, and disputes over traditional burial customs led to at least three attacks on health centers. Contact tracing has lagged badly: by late May, more than 1,600 contacts had been identified in Ituri, but only about a fifth were being successfully followed up, hampered by insecurity and population movement.

The international response has stiffened. Uganda and Rwanda closed their borders with the DRC, the United States barred most travelers from affected regions and pledged more than 112 million dollars in aid, and the European Union sent medical supplies to Ituri.

Brazil and Italy: Scares That Were Ruled Out

As the outbreak grew, three suspected cases abroad triggered emergency protocols and brief alarm. All three were ultimately ruled out.

• In Sao Paulo, Brazil, health authorities cleared a man who had recently traveled to Congo. His Ebola tests came back negative, and he was instead found to have meningitis.
• In Rio de Janeiro, a traveler who had come from Uganda and contracted malaria tested negative for Ebola through saliva and urine testing.
• In Cagliari, on the Italian island of Sardinia, a man who had flown back from Congo and developed symptoms prompted hospital isolation protocols before testing negative.

No Ebola cases have been confirmed outside the DRC and neighboring Uganda. The false alarms, resolved within days, underscored how closely health systems far from central Africa are now watching travelers from the region, and how quickly modern laboratory testing can distinguish Ebola from the malaria, meningitis, and other febrile illnesses it can resemble in its early stages.

What Comes Next

The trajectory over the coming weeks will hinge on whether responders can lift contact tracing above its current low follow-up rate, sustain access to insecure areas, and keep treatment centers running long enough for supportive care to do its work. The absence of an approved vaccine removes the single most powerful tool that ended recent Zaire-strain outbreaks, leaving classic public health measures, isolation, tracing, safe burials, and community trust, to carry the load.

For now, the recoveries in Bunia offer a measure of what is possible. "We can stop this Ebola," Tedros said, and in the same breath made clear how much work that will take.